Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

G1 Therapeutics Inc (NQ: GTHX )

1.440 +0.090 (+6.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 445,210
Open 1.360
Bid (Size) 1.450 (1)
Ask (Size) 1.490 (3)
Prev. Close 1.350
Today's Range 1.340 - 1.440
52wk Range 1.220 - 13.85
Shares Outstanding 42,705,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Black Diamond Therapeutics Announces CEO Transition
From Black Diamond Therapeutics, Inc
Via GlobeNewswire

Performance

YTD
-74.87%
-74.87%
1 Month
-17.24%
-17.24%
3 Month
-42.17%
-42.17%
6 Month
-46.27%
-46.27%
1 Year
-88.10%
-88.10%

More News

Read More
Analyst Ratings for G1 Therapeutics
Via Benzinga
G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
From G1 Therapeutics
Via GlobeNewswire
Where G1 Therapeutics Stands With Analysts
Via Benzinga
Recap: G1 Therapeutics Q1 Earnings
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Earnings Preview: G1 Therapeutics
Via Benzinga
What 6 Analyst Ratings Have To Say About G1 Therapeutics
Via Benzinga
Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy
From G1 Therapeutics
Via GlobeNewswire
New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer
From G1 Therapeutics
Via GlobeNewswire
New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)
From G1 Therapeutics
Via GlobeNewswire
7 Analysts Have This to Say About G1 Therapeutics
Via Benzinga
Earnings Scheduled For March 1, 2023
Via Benzinga
G1 Therapeutics's Earnings Outlook
Via Benzinga
Benzinga Pro's Top 5 Stocks To Watch For Tuesday, May 9, 2023: BABA, TSM, LCID, H, GTHX
Via Benzinga
G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
Dow Gains Over 300 Points; S&P 500 Up 1%
Via Benzinga
Why Frequency Therapeutics Are Trading Lower By 82%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Nasdaq Rises 1.5%; G1 Therapeutics Shares Plummet
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.